ArticleJACC. Case reports2025
Imaging Pitfalls in the Detection of Infiltrative Cardiomyopathies.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite increasing recognition of infiltrative cardiomyopathies, the heterogeneous group of diseases remains difficult to diagnose. CASE SUMMARY: We present an 82-year-old man with septal basal thickening initially thought to be hypertrophic cardiomyopathy. Further imaging was suspicious for sarcoidosis, but after several years without clinical improvement and the interval development of concentric hypertrophy, he was diagnosed with cardiac amyloidosis. DISCUSSION: Advanced imaging modalities are frequently used to evaluate suspected infiltrative cardiomyopathies. However, the effectiveness of imaging can be limited by the variable presentations of both sarcoid and amyloid. In this case, cardiac amyloidosis initially appeared on imaging with features characteristic of cardiac sarcoidosis on both positron emission tomography and cardiac magnetic resonance. Despite advancements in imaging technology, diagnostic limitations persist, potentially leading to misdiagnosis and delayed treatment. TAKE-HOME MESSAGES: Despite increasing recognition, cardiac amyloid and cardiac sarcoid are difficult to diagnose and require a high degree of clinical suspicion. Multimodality imaging can help discriminate between cardiomyopathies. However, limitations with current imaging modalities may lead to further diagnostic uncertainty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.